PuSH - Publication Server of Helmholtz Zentrum München

Ha, C.S.R. ; Müller-Nurasyid, M. ; Petrera, A. ; Hauck, S.M. ; Marini, F.* ; Bartsch, D.K.* ; Slater, E.P.* ; Strauch, K.

Proteomics biomarker discovery for individualized prevention of familial pancreatic cancer using statistical learning.

PLoS ONE 18:e0280399 (2023)
DOI PMC
Creative Commons Lizenzvertrag
Open Access Gold as soon as Publ. Version/Full Text is submitted to ZB.
BACKGROUND: The low five-year survival rate of pancreatic ductal adenocarcinoma (PDAC) and the low diagnostic rate of early-stage PDAC via imaging highlight the need to discover novel biomarkers and improve the current screening procedures for early diagnosis. Familial pancreatic cancer (FPC) describes the cases of PDAC that are present in two or more individuals within a circle of first-degree relatives. Using innovative high-throughput proteomics, we were able to quantify the protein profiles of individuals at risk from FPC families in different potential pre-cancer stages. However, the high-dimensional proteomics data structure challenges the use of traditional statistical analysis tools. Hence, we applied advanced statistical learning methods to enhance the analysis and improve the results' interpretability. METHODS: We applied model-based gradient boosting and adaptive lasso to deal with the small, unbalanced study design via simultaneous variable selection and model fitting. In addition, we used stability selection to identify a stable subset of selected biomarkers and, as a result, obtain even more interpretable results. In each step, we compared the performance of the different analytical pipelines and validated our approaches via simulation scenarios. RESULTS: In the simulation study, model-based gradient boosting showed a more accurate prediction performance in the small, unbalanced, and high-dimensional datasets than adaptive lasso and could identify more relevant variables. Furthermore, using model-based gradient boosting, we discovered a subset of promising serum biomarkers that may potentially improve the current screening procedure of FPC. CONCLUSION: Advanced statistical learning methods helped us overcome the shortcomings of an unbalanced study design in a valuable clinical dataset. The discovered serum biomarkers provide us with a clear direction for further investigations and more precise clinical hypotheses regarding the development of FPC and optimal strategies for its early detection.
Altmetric
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords Binding Protein; R Package; Expression; Risk; Adenocarcinoma; Regularization; Prediction; Molecule; Homolog; Cloning
ISSN (print) / ISBN 1932-6203
Journal PLoS ONE
Quellenangaben Volume: 18, Issue: 1, Pages: , Article Number: e0280399 Supplement: ,
Publisher Public Library of Science (PLoS)
Publishing Place Lawrence, Kan.
Non-patent literature Publications
Reviewing status Peer reviewed
Grants GAUFF-Foundation
German Research Foundation
Munich Center of Health Sciences (MC-Health), Ludwig Maximilian University of Munich, as part of LMUinnovativ
Wilhelm Sander-Stiftung